(S (NP-SBJ (NP (NN Activation)) (PP (IN of) (NP (JJ human) (JJ monocytic) (NNS cells))) (PP (IN by) (NP-COOD (NP (NP-COOD (NP (FW Treponema) (FW pallidum)) (CC and) (NP (FW Borrelia) (FW burgdorferi))) (NNS lipoproteins)) (CC and) (NP (JJ synthetic) (NNS lipopeptides))))) (VP-COOD (VP (VBZ proceeds) (PP (IN via) (NP (NP (DT a) (NN pathway)) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (NN lipopolysaccharide))))))))) (CC but) (VP (VBZ involves) (NP (DT the) (JJ transcriptional) (NN activator) (NN NF-kappa) (NN B)))) (. .))
(S (NP-SBJ (EX There)) (VP (VBZ is) (NP-PRD (VBG increasing) (NN evidence) (SBAR (IN that) (S (NP-SBJ (NP (NNS lipoproteins)) (PP (IN of) (NP-COOD (NP (FW Treponema) (FW pallidum)) (CC and) (NP (FW Borrelia) (FW burgdorferi))))) (VP (VBP are) (NP-PRD (JJ key) (JJ inflammatory) (NNS mediators)) (PP-TMP (IN during) (NP-COOD (NP (NN syphilis)) (CC and) (NP (NN Lyme) (NN disease))))))))) (. .))
(S (NP-SBJ (NP (DT A) (JJ principal) (NN objective)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBD was) (S-PRD (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB identify) (ADVP (RBR more) (RB precisely)) (NP (NP-COOD (NP (NNS similarities)) (CC and) (NP (NNS divergences))) (PP (IN among) (NP (ADJP-COOD (ADJP (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-)) (: -)) (ADJP (-NONE- *?*))) (CC and) (ADJP (JJ lipoprotein-lipopeptide-induced))) (JJ immune) (NN cell) (NN signaling) (NNS events)))))))) (. .))
(S (PP (IN Like) (NP (NN LPS))) (, ,) (NP-SBJ (NP-COOD (NP (VBN purified) (JJ native) (FW B.) (FW burgdorferi) (NN OspA)) (CC and) (NP (NP (JJ synthetic) (NNS analogs)) (PP (IN of) (NP-COOD (NP (NN OspA)) (, ,) (NP (NN OspB)) (, ,) (CC and) (NP (NP (CD two) (FW T.) (FW pallidum) (NNS lipoproteins)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN Tpp47)) (CC and) (NP (NN Tpp17))) (-RRB- -RRB-))))))) (NP (DT all))) (VP (VBD induced) (NP (NP (NN NF-kappa) (NN B) (NN translocation)) (PP (IN in) (NP (NN THP-1) (JJ human) (NN monocytoid) (NNS cells))))) (. .))
(S (NP-SBJ (NP (NN Acylation)) (PP (IN of) (NP-COOD (NP (NN OspA)) (CC and) (NP (DT the) (JJ synthetic) (NNS peptides))))) (VP (VBD was) (ADJP-PRD (JJ requisite) (PP (IN for) (NP (NN cell) (NN activation))))) (. .))
(S (NP-SBJ (NN Polymyxin) (NN B)) (VP (VBD abrogated) (NP (NP (RB only) (DT the) (NN response)) (PP (TO to) (NP (NN LPS))))) (. .))
(S (PP (IN By) (S (NP-SBJ (-NONE- *)) (VP (VBG using) (NP (NP (JJ (3-derived 70Z)) (NN pre-B-cell) (NNS lines)) (VP (VP-COOD (CC either) (VP (VBG lacking) (NP (-NONE- *RNR*-32))) (CC or) (VP (VBG expressing) (NP (-NONE- *RNR*-32)))) (NP-32 (NP (JJ human) (NN CD14)) (PRN (-LRB- -LRB-) (NP (DT the) (NN LPS) (NN receptor)) (-RRB- -RRB-)))))))) (, ,) (NP-SBJ (PRP it)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (JJ human) (NN CD14)))) (VP (VBD imparted) (NP (NP (NN responsiveness)) (PP-COOD (PP (TO to) (NP (NN LPS))) (CC but) (PP (RB not) (TO to) (NP-COOD (NP (NN OspA)) (CC or) (NP (JJ spirochetal) (NNS lipopeptides)))))) (PRN (-LRB- -LRB-) (S (NP-SBJ-100 (-NONE- *)) (VP (VBN assessed) (NP (-NONE- *-100)) (PP (IN by) (NP-COOD (NP (NP (NN induction)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (CC and) (NP (NP (NN expression)) (PP (IN of) (NP (NN surface) (NN immunoglobulin) (NN M)))))))) (-RRB- -RRB-))))))) (. .))
(S (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ-33 (NP (DT the) (JJ biological) (NN relevance)) (PP (IN of) (NP (DT the) (NN observation) (SBAR (IN that) (S (NP-SBJ (FW T.) (FW pallidum) (NNS lipoproteins-lipopeptides)) (VP (VBP induce) (NP (NP (NP-COOD (CC both) (NP (NN NF-kappa) (NN B)) (CC and) (NP (NN cytokine))) (NN production)) (PP (IN in) (NP (NNS monocytes)))))))))) (VP (VBD was) (VP (VBN supported) (NP (-NONE- *-33)) (PP (IN by) (NP-LGS (NP (DT the) (NN ability) (S (-NONE- *ICH*-34))) (PP (IN of) (NP (DT the) (JJ synthetic) (NNS analogs))) (S-34 (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB promote) (NP (JJ human) (NN immunodeficiency) (NN virus) (NN replication)) (PP (IN in) (NP (ADJP (RB chronically) (JJ infected)) (NN U1) (NN monocytoid) (NNS cells)))))))))) (: ;)) (S (NP-SBJ (DT these) (NNS observations)) (ADVP (RB also)) (VP (VBP suggest) (NP (NP (DT a) (JJ potential) (NN mechanism)) (SBAR (WHADVP-35 (WRB whereby)) (S (NP-SBJ (DT a) (JJ syphilitic) (NN chancre)) (VP (MD can) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN cofactor)) (PP (IN for) (NP (JJ human) (NN immunodeficiency) (NN virus) (NN transmission))))) (ADVP (-NONE- *T*-35)))))))) (. .)))
(S (NP-SBJ (DT The) (JJ combined) (NNS data)) (VP (VBP lend) (NP (JJ additional) (NN support)) (PP (TO to) (NP (DT the) (NN proposal) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-COOD (NP (JJ spirochetal) (NNS lipoproteins)) (CC and) (NP (NN LPS))) (VP (VBP initiate) (NP (NN monocyte) (NN activation)) (PP (IN via) (NP (JJ different) (NN cell) (NN surface) (NNS events)))))) (CC but) (SBAR (IN that) (S (NP-SBJ-36 (DT the) (NN signaling) (NNS pathways)) (ADVP (RB ultimately)) (VP (VBP converge) (S (NP-SBJ (-NONE- *-36)) (VP (TO to) (VP (VB produce) (NP (ADJP (RB qualitatively) (JJ similar)) (JJ cellular) (NNS responses)))))))))))) (. .))
